CareDx's prelim Q4 revenue beats estimates on higher testing volumes

CareDx

12/01/2026 12:15

Overview

Transplant solutions firm's preliminary Q4 revenue grew 25% yr/yr, beating analyst expectations

Company repurchased $12 mln worth of shares during the quarter

Preliminary full year revenue reached $380 mln, up 14% yr/yr

Outlook

Company plans to advance Transplant+ innovation pipeline in 2026

Result Drivers

TESTING SERVICES GROWTH - Testing services revenue increased 23% yr/yr, driven by a 17% rise in testing volume

PATIENT & DIGITAL SOLUTIONS - Revenue from patient and digital solutions grew 47% yr/yr, indicating strong demand

STRATEGIC FOCUS - Co's solutions selling strategy contributed to record revenue, with plans to advance Transplant+ pipeline in 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$108 mln
$102.58 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CareDx Inc is $24.50, about 43% above its January 9 closing price of $17.13

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nBwb8tSfza

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)